Drugs / zamtocabtagene autoleucel
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06708845 | Jul 2026 → Jan 2028 expected | diffuse cutaneous systemic sclerosis, lupus nephritis, systemic lupus erythematosus | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT03870945 | Feb 2019 → Dec 2020 | B-cell non-Hodgkin lymphoma | Miltenyi Biomedicine GmbH | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07569965 | Sep 2026 → Sep 2029 expected | mantle cell lymphoma | Miltenyi Biomedicine GmbH | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06508931 | Aug 2025 → Dec 2029 expected | B-cell neoplasm | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT04792489 | May 2021 → Dec 2026 expected | Richter transformation, central nervous system non-hodgkin lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +1 | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zamtocabtagene autoleucel | “Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.” PMID 41512222 ↗ Apr 2026 |
| Known as | MB-CART2019.1 | “the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma” NCT04792489 ↗2“Zamtocabtagene autoleucel (MB-CART2019.1) is a tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.” NCT06508931 ↗ “zamtocabtagene autoleucel (MB-CART2019.1)” NCT07569965 ↗ |
| Known as | zamto-cel | “AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non...” NCT06708845 ↗1“first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy” PMID 41512222 ↗ Apr 2026 |
| Modality | Cell therapy | “a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy” PMID 41512222 ↗ Apr 2026 |
| Route | Intravenous | “The IMP will be administered as an intravenous infusion.” NCT03870945 ↗ |
| Target | CD19 | “genetically modified to express anti-CD20 and CD19 immunoreceptor” NCT03870945 ↗ |